Summary: Treatment-Naive Genotype 1b Without Cirrhosis
Recommended and alternative regimens listed by pangenotypic, evidence level and alphabetically for:
Treatment-Naive Patients Genotype 1b Without Cirrhosis
|
|
RECOMMENDED
|
DURATION
|
RATING 
|
|
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)a
|
8 weeks
|
I, A
|
|
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)
|
12 weeks
|
I, A
|
|
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)
|
12 weeksb
|
I, A
|
|
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)
|
12 weeks
|
I, A
|
|
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for patients who are HIV-uninfected and whose HCV RNA level is <6 million IU/mL
|
8 weeksc
|
I, B
|
a Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.
b For HIV/HCV coinfected patients, a treatment duration of 12 weeks is recommended.
c An 8-week regimen can be considered in those with genotype 1b infection and mild fibrosis (see text for details).
|
